DMK Pharmaceuticals (FRA:CY3) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is DMK Pharmaceuticals 3-Year Dividend Growth Rate?

DMK Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2023 was €0.00.

The historical rank and industry rank for DMK Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

FRA:CY3's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 11
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

DMK Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, DMK Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of DMK Pharmaceuticals's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's 3-Year Dividend Growth Rate falls into.

DMK Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

DMK Pharmaceuticals (FRA:CY3) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

DMK Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.336
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>

DMK Pharmaceuticals (FRA:CY3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (FRA:CY3) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

DMK:USA

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (FRA:CY3) Headlines

No Headlines